Organism: Homo sapiens
Gene: 38672_at
Selected probe(set): 201702_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38672_at (201702_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-3.0799904
Number of Samples:3 / 4

Experimental	R547 study 1 (2h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 2 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 2 hours.

Relative Expression (log2-ratio):2.9644728
Number of Samples:20 / 19

Experimental	atopic dermatitis study 12 (non-lesional; adults)
	Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis.
Control	atopic dermatitis study 12 (non-lesional; children)
	Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded.

Relative Expression (log2-ratio):2.842618
Number of Samples:4 / 3

Experimental	tumor supernatant activation study 3
	Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control	untreated memory CD4 T-cell sample
	Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

Relative Expression (log2-ratio):2.7697
Number of Samples:4 / 3

Experimental	tumor supernatant activation study 3
	Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control	memory T-cell activation study 1
	Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

Relative Expression (log2-ratio):-2.7565575
Number of Samples:2 / 4

Experimental	R547 study 1 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

Relative Expression (log2-ratio):-2.739647
Number of Samples:4 / 4

Experimental	R547 study 3 (2h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 2 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 2 hours.

Relative Expression (log2-ratio):2.683754
Number of Samples:43 / 4

Experimental	adrenal gland cancer study 4
	Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC).
Control	normal adrenal cortex tissue
	Histological normal adrenal gland cortical tissue samples derived after autopsy.

Relative Expression (log2-ratio):2.6154156
Number of Samples:6 / 12

Experimental	IL-4; GM-CSF study 1 (early)
	Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control	untreated monocyte sample
	Freshly isolated human monocytes from healthy donors.

Relative Expression (log2-ratio):-2.5562677
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.4311333
Number of Samples:3 / 4

Experimental	R547 study 3 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.